Poster

Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

I am a Healthcare Professional registered to practice in the U.S.
I am a U.S. Patient or Caregiver
MENU